On June 11, 2021, Akeso, Inc. (9926.HK) announced that, the company has signed agreement with Shanghai Municipal Minhang District South Hongqiao Management Committee Office and Huacao Town Government to build the Shanghai International Center Project.
The construction of this project is an important step to further consolidate Akesobio’s pharmaceutical innovation and commercial operation system.
Shanghai has always been one of the most influential regions for biopharma industry innovation, with its sound and advanced industrial system, enriched innovation elements, high level of internationalization, nationally-leading R&D innovation capability, as well as its sustained and rapid growth of the industry scale. To further boost the development of Shanghai’s biopharma industry and accelerate building a world-class biopharma industrial cluster, the Municipal Government of Shanghai has recently enacted and issued “the Measures to Boost High-Quality Development of the Biopharmaceutical Industry”.
Michelle Xia, President & CEO of Akesobio, PhD, expressed that:
With the advantages of Shanghai’s international economic status, top talents and research institutes’ cluster, via this project, we hope to perfect the internationalized innovative R&D and commercialization platform, further enhance the Yangtze River Delta strategic development plan with Shanghai as the center. It is Akesobio’s mission to promote or even to lead the innovation development of China’s biopharma industry as a Chinese antibody drug R&D pioneer and practitioner. Akesobio is determined to become part of the important carrier of China’s domestic economic cycle, meanwhile expecting to connect the domestic and international economic cycles. Akesobio is looking forward to make contribution to China’s biopharma industry together with the city of Shanghai.
